Study in mice suggests drug could bring new benefits in treating depression by lifting mood within hours, plus offer sustained effectiveness
For someone with depression in the midst of a crisis, there is no time to waste. Yet time is exactly what currently-available antidepressants require to take effect—often on the order of weeks.
A new study suggests a fast-acting antidepressant may be on the horizon. In mice, the drug produces evidence of a mood lift within 24 hours and then continues working for sustained relief.
“What makes this study unique and exciting is that in the same drug we seem to have both of the properties you want in an antidepressant—both rapid and sustained effects,” said Jeffery Talbot, Ph.D., director of the Research Center on Substance Abuse and Depression at Roseman University of Health Sciences and one of the study’s lead investigators.
Though many drugs are currently available to treat people with depression, existing drugs do not work quickly, and they do not work for everyone. “Many people with depression simply don’t respond to available medications,” said Talbot. “There’s still a real need for new antidepressants.”
The drug, referred to by Talbot as its coded name MI-4 and better known among scientists as Ro-25-6981, has been shown by previous researchers to cause a rapid antidepressant effect in animals by blocking one of the brain’s signaling chemicals. But until now, researchers were not aware of the full spectrum of its antidepressant properties.
The new study bolsters the evidence for MI-4’s rapid effect and adds an exciting twist: MI-4 also works in the long term. Moreover, it may accomplish its long-term effects through a three-pronged approach known as triple reuptake inhibition, which refers to a drug’s ability to simultaneously increase the levels of three key chemicals in the brain that are known to affect mood and feelings of pleasure—dopamine, norepinephrine and serotonin. Most depression drugs only target one of these chemicals, which may explain why they are not effective in all patients.
The researchers found MI-4 via “virtual screening,” a method that uses computer modeling to find drugs that are likely to interact with particular receptors in the brain. “From looking at its structure, one would never have guessed that this drug interacts with the same monoamine transporter proteins as does Paxil or cocaine, but it does. That speaks to the ‘needle in a haystack’ detection power of the virtual screening methodology,” said Christopher Surratt, Ph.D., a professor of pharmacology working on this aspect of the study at Duquesne University.
Following the virtual screening, the researchers tested MI-4’s effects in cell cultures and then in mice. In addition to providing new evidence of its antidepressant properties, the study shows MI-4 would be unlikely to become addictive.
Depression is one of the most common mental illnesses in the world, affecting about 20 million people in the United States. Causing persistent sadness and loss of energy, it can take an enormous toll on a person’s ability to work or have healthy personal relationships and is a leading cause of suicide.
Antidepressants are some of the most commonly prescribed medications, with 264 million prescriptions written for antidepressants in 2011 totaling more than $11 billion in sales.
The Latest on: Antidepressant
via Google News
The Latest on: Antidepressant
- Botulinum Toxin Linked to Antidepressant Effectson August 12, 2020 at 10:26 am
A study using safety surveillance data of botulinum toxin found significant associations between its use and antidepressant effects, across several indications and different injection sites, according ...
- Global Tricyclic Antidepressant Market 2020 Industry Growth Analysis by Key Players, Segments, Competitive Landscape and Forecast to 2025on August 11, 2020 at 5:09 pm
The recent market research study Global Tricyclic Antidepressant Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 is a complete assessment of current market status, ...
- Antidepressant Drugs Market Phenomenal Growth Prospects, Opportunities and Threats| Bristol Myers Squibb Co., Allergan Plc and Alkermes Plcon August 8, 2020 at 11:51 pm
Aug 09, 2020 (WiredRelease via Comtex) -- Antidepressant Drugs Market Overview: The report provides each quantitative and qualitative information of the global Antidepressant Drugs market for the ...
- Ketamine’s promise as an antidepressant is being undermined by its lack of profiton August 7, 2020 at 4:59 pm
The FDA approved a drug, esketamine, that can help with depression. But some psychiatrists question why ketamine, its cheaper cousin, isn't being similarly developed.
- Nasal Spray Is A New Antidepressant Option For People At High Risk of Suicideon August 7, 2020 at 2:30 pm
"Spravato is the first approved antidepressant medication that's been able to demonstrate a reduction in symptoms of major depressive disorder within 24 hours after the first dose," says Dr ...
- Nasal Spray Is A New Antidepressant Option For People At High Risk of Suicideon August 7, 2020 at 2:18 pm
Doctors have a new option for suicidal patients. It's a fast-acting nasal spray containing a version of the anesthetic ketamine.
- Antidepressant Drugs Market to Grow Valuation of $15.98 Billion by 2023on August 6, 2020 at 7:31 am
The increase in awareness in regards with the disease state and importance of clinical needs, and rise in prevalence of depression are the major driving factors that are projected to boost the market ...
- Trajectories of antidepressant medication use during pregnancyon August 4, 2020 at 9:23 pm
In an analysis of women who started pregnancy when taking antidepressant medications, investigators identified three trajectories of antidepressant dispensing during pregnancy: more than half stopped ...
- US health chiefs approve antidepressant nasal spray derived from party drug ketamine to treat suicidal peopleon August 4, 2020 at 5:09 am
Spravato - made by American pharmaceutical and consumer giant Johnson and Johnson - has been given the green light by the Food and Drug Administration. The spray works in four hours.
via Bing News